摘要
目的研究肺癌体外化疗药物敏感性与临床疗效的关系,为临床化疗方案的个体化选择提供依据。方法60例非小细胞肺癌病例入组,试验组使用ATP-TCA方法测定肺癌组织中肿瘤细胞的化疗药物敏感性,并依据敏感结果选择化疗方案;对照组选择NP方案。观察临床近期疗效和远期生存率。结果试验组有效率43.48%,2年生存率34.78%,高于NP方案组的37.04%和25.92%,但是两组之间没有明显差异。结论依靠体外药敏试验结果指导化疗方案的制定可能有助于肺癌化疗疗效的提高。
Objective Evasluate the adenosine triphosphate tumor chemosensitivity assay （ATP-TCA） in guiding clinical chemotherapy for non-small-cell lung cancer （NSCLC） patients. Methods ATP-TCA was applied to test efficacies of 15 different drugs. 23 patients received ATP-TCA-directed chemotherapy; the other 27 patients received NP regimen （control group） . Clinical outcome were observed. Results ATP-TCA group have the response rate of 43.38%, a little higher than the control group of 37. 04%. The 2-year over all survival rate is 34. 78% in ATP-TCA group and 25.92% in control group. Conclution ATP-TCA might be useful in planning individualized chemotherapy regimen for NSCLC patients.
出处
《广州医药》
2006年第1期24-27,共4页
Guangzhou Medical Journal
基金
广东省卫生厅课题
编号A2002617
粤卫[2002]119号
关键词
非小细胞肺癌
药敏实验
药物疗法
个体化疗
Non-small-cell lung cancer
Chemo-drug sensitive test
Drug therapy
Individual treatment
